What the FDA labels say about taking them together
Ensitrelvir and enzalutamide
Ensitrelvir's FDA label of June 3, 2026 names enzalutamide in its drug interactions section; the enzalutamide labels PlainMeds reads (2) do not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to potential loss of virologic response.”
Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the enzalutamide FDA label on DailyMed (effective July 28, 2026, Astellas Pharma US, Inc.).
What does the ensitrelvir label say about enzalutamide?
Ensitrelvir label, drug interactionsDrug Class: Anticancer drugs; Drug (s) within Class: apalutamide, enzalutamide; Effect on Drug Concentration: ↓ ensitrelvir; Clinical Comment: Co-administration is contraindicated due to potential loss of virologic response.
Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed
What does the enzalutamide label say about ensitrelvir?
Enzalutamide's label (effective July 28, 2026) and its 1 other brand-application label do not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xtandi), Astellas Pharma US, Inc., effective July 28, 2026 (SPL set b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ensitrelvir | Enzalutamide | |
|---|---|---|
| Labeled for | COVID-19 | Prostate cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once